"
Team:Peking R/HumanPractice/Investigation
From 2011.igem.org
Grasscliff (Talk | contribs) |
Grasscliff (Talk | contribs) |
||
| Line 13: | Line 13: | ||
top:319px; | top:319px; | ||
width:655px; | width:655px; | ||
| - | height: | + | height:2023px; |
z-index:2; | z-index:2; | ||
font-family: "Comic Sans MS", cursive; | font-family: "Comic Sans MS", cursive; | ||
| Line 102: | Line 102: | ||
position:absolute; | position:absolute; | ||
left:561px; | left:561px; | ||
| - | top: | + | top:2303px; |
width:130px; | width:130px; | ||
height:28px; | height:28px; | ||
| Line 257: | Line 257: | ||
The first few questions look into the extent to which antibiotics and antibiotic-resistant bacteria (ARB) are employed in laboratory research. It may be seen that over eighty percent of laboratories use ARB for at least half of their experiments (Q2), and that approximately one fifth of them use bacteria with multi-antibiotic resistance (Q3). Therefore, there exists a large pool of antibiotic resistance that is foreseeable threats to the environment.<br /> | The first few questions look into the extent to which antibiotics and antibiotic-resistant bacteria (ARB) are employed in laboratory research. It may be seen that over eighty percent of laboratories use ARB for at least half of their experiments (Q2), and that approximately one fifth of them use bacteria with multi-antibiotic resistance (Q3). Therefore, there exists a large pool of antibiotic resistance that is foreseeable threats to the environment.<br /> | ||
Question 2</p> | Question 2</p> | ||
| - | <p class="clickteam"><img src=" | + | <p class="clickteam"><img src="https://static.igem.org/mediawiki/2011/4/40/PwekingR_hp_Q2.png" width="500" height="282" hspace="50" /></p> |
<p class="clickteam"><br /> | <p class="clickteam"><br /> | ||
Question 3</p> | Question 3</p> | ||
| - | <p class="clickteam"><img src=" | + | <p class="clickteam"><img src="https://static.igem.org/mediawiki/2011/9/92/PekingR_hp_Q3.png" width="500" height="385" hspace="50" /><br /> |
</p> | </p> | ||
<table border="0" cellspacing="0" cellpadding="0" width="397"> | <table border="0" cellspacing="0" cellpadding="0" width="397"> | ||
Revision as of 11:54, 20 September 2011
Template:Https://2011.igem.org/Team:Peking R/bannerhidden Template:Https://2011.igem.org/Team:Peking R/back2 Template:Https://2011.igem.org/Team:Peking R/Humanpracticebackground
Investigation of Antibiotic Use and
Related Biosafety Issues: What's
happening out there and further.
In order to investigate the extent to which laboratories understand biosafety issues in regard to antibiotic use, we have carried out a survey involving about 150 participants (including researchers from laboratories in the College of Life sciences and College of Chemistry and Molecular Engineering in Peking University, and employees at a few sequencing companies) who responded to a series of questions related with treatment of antibiotic-resistant bacteria in the laboratory. (For the majority of the participants, who are non-English speakers, a Chinese version of the questionnaire was provided so that difficulties in understanding survey questions were minimized.)
According to the responses given by the number of participants who have responded, it may be concluded that, in general, laboratory researchers are aware of potential safety issues related with the use of antibiotic and resistance genes, but the level of awareness is far from sufficient for restricting laboratory work in a way that minimizes possible hazards as a consequence of microbes’ antibiotic resistance.
The first few questions look into the extent to which antibiotics and antibiotic-resistant bacteria (ARB) are employed in laboratory research. It may be seen that over eighty percent of laboratories use ARB for at least half of their experiments (Q2), and that approximately one fifth of them use bacteria with multi-antibiotic resistance (Q3). Therefore, there exists a large pool of antibiotic resistance that is foreseeable threats to the environment.
Question 2
Question 3
A.Mostly multi-antibiotic resistant(2.56%) |
|
B.Half are multi-antibiotic resistant(17.95%) |
|
C.Only a few are multi-antibiotic resistant(46.15%) |
|
D.Almost none(33.33%) |
|
The next set of questions investigates whether used or unwanted ARB is appropriately processed in laboratories.
